Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin + Immune Checkpoint Inhibitor in Metastatic Breast Cancer
NCT05318469Phase 2Recruiting
- Sponsor
- Yuanyuan Biotech
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CHILD-IVITAB in breast cancer, sponsored by Yuanyuan Biotech. Started Oct 2023; status: recruiting.
02
Drugs
CHILD-IVITAB
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05318469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318469.